$395.60 million is the projected 2034 size for the implantable tibial neuromodulation systems market, up from $72.33 million in 2026 and $53.17 million in 2025.
23.7% annual growth is being driven by rising untreated urge urinary incontinence and overactive bladder cases, plus demand for durable non-drug therapies that sit between medication and more invasive neuromodulation.
Battery-powered implants led the market in 2025, while the urge urinary incontinence segment is expected to hold 81.8% of 2026 revenue and hospitals and ASCs 54.2%.
North America remained the largest region, reaching $53.17 million in 2025 on earlier FDA approvals, reimbursement progress and the presence of BlueWind Medical, Medtronic and Valencia Technologies.
Reimbursement gaps, procedure costs and limited physician training still threaten wider adoption, even as companies push miniaturized, low-maintenance and externally powered systems.